Center for Cancer Immune Therapy (CCIT)

Medicine & Life Sciences

1. Adoptive Transfer 9%
2. Antibodies 5%
3. Antigens 19%
4. Arginase 9%
5. Biomarkers 6%
6. Breast Neoplasms 6%
7. Calreticulin 12%
8. Cancer Vaccines 12%
9. Castration 6%
10. Cell- and Tissue-Based Therapy 21%
11. Chimeric Antigen Receptors 6%
12. Clinical Trials 5%
13. Clinical Trials, Phase I 5%
14. Clone Cells 5%
15. Collagen 5%
16. Cutaneous T-Cell Lymphoma 5%
17. Cytokines 7%
18. Cytotoxic T-Lymphocytes 5%
19. Dendritic Cells 34%
20. Epitopes 19%
21. Hematologic Neoplasms 5%
22. Histocompatibility Antigens Class I 6%
23. HLA Antigens 6%
24. HLA-A2 Antigen 7%
25. Immune System 9%
26. Immunity 9%
27. Immunosuppressive Agents 5%
28. Immunotherapy 42%
29. In Vitro Techniques 5%
30. Indoleamine-Pyrrole 2,3,-Dioxygenase 21%
31. Interferons 7%
32. Interleukin-2 10%
33. Ipilimumab 21%
34. Ligands 10%
35. Major Histocompatibility Complex 5%
36. Melanoma 84%
37. Monocytes 5%
38. Mutation 7%
39. Natural Killer Cells 6%
40. Neoplasm Antigens 21%
41. Neoplasms 65%
42. Nivolumab 13%
43. Ovarian Neoplasms 8%
44. Pancreatic Neoplasms 6%
45. pembrolizumab 6%
46. Peptides 29%
47. Phenotype 6%
48. Polycythemia Vera 5%
49. Population 5%
50. Progression-Free Survival 6%
51. Prostatic Neoplasms 6%
52. Proteins 6%
53. Regulatory T-Lymphocytes 10%
54. Renal Cell Carcinoma 7%
55. Subunit Vaccines 12%
56. Survival 15%
57. Survivin 8%
58. T-Cell Antigen Receptor 7%
59. T-Lymphocyte Epitopes 5%
60. T-Lymphocytes 100%
61. Therapeutics 21%
62. Tissue Donors 6%
63. Tumor Microenvironment 21%
64. Tumor-Infiltrating Lymphocytes 51%
65. Vaccination 34%
66. Vaccines 19%